Contact us

Contact us at the address, e-mail or telephone number below and we'll get back to you as soon as possible.

DAVID eHealth & Pharma UG,
Saarland University,
Starterzentrum, Building A1 1,
66123, Saarbruecken
Germany

This email address is being protected from spambots. You need JavaScript enabled to view it.

+49-151-51700933

Didn't we got you connected? Please note the following magic buttons:

Want to place your Ads or News on World Pharma News?

World Pharma News is one of the most visited sites on the Internet for pharmaceutical business decision-makers, professionals and stakeholders looking for the latest breaking news on the global market and in-depth research news articles. Why not put this traffic to work for you? It costs only a fraction of other on-line publications, which have far fewer readers.

We have the solutions that meet your ambitious marketing objectives. We offer flexible and price-worthy advertising opportunities for you to take advantage of. These include:

  • Skyscraper Banner, 120px / 600px (left-top, left-bottom)
  • Medium Rectangle Banner, 300px / 250px (right-top, medium and right-bottom)
  • Standard Banner, 468px / 60px (middle-top and middle-bottom)
  • Leaderboard Banner, 728px / 90px (top and bottom)
  • Newsletter Ads

The strong, innovative capabilities of World Pharma News can support your advertising, news promotion and news distribution campaigns. You will reach your objectives and an unique audience of top pharma professionals, key players and decision makers.

Don't Be Shy. If we didn’t answer all of your questions, feel free to drop us a line anytime.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

AstraZeneca divests rights to established hyperten…

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Ze...

Botanical drug is shown to help patients with head…

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are locat...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...